Holen Sie sich die Stockscreener-App
1.49
7.45%
-0.12
Handel nachbörslich:
1.43
-0.06
-4.03%
Actinium Pharmaceuticals Inc Aktie (ATNM) Neueste Nachrichten
ATNM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - markets.businessinsider.com
ACTINIUM ALERT: Bragar Eagel & Squire, P.C. Announces that - GlobeNewswire
Actinium Pharmaceuticals, Inc. Shareholder Notice: Robbins LLP Reminds Investors of the Class Action Against ATNM - GlobeNewswire
Actinium Pharmaceuticals, Inc. Shareholder Notice: Robbins LLP Reminds Investors of the Class Action Against ATNM - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesATNM - PR Newswire
ROSEN, A TOP RANKED LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure - Bluefield Daily Telegraph
ATNM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - markets.businessinsider.com
ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TradingView
ATNM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Actinium Pharmaceuticals, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium - GlobeNewswire
ATNM Investors Have Opportunity to Lead ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit - The Malaysian Reserve
What is HC Wainwright’s Forecast for ATNM FY2027 Earnings? - Defense World
Indo-Asian News Service - IANS India Pvt Ltd
ATNM ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Actinium Pharmaceuticals, Inc. Investors - TradingView
Investor Alert: Robbins LLP Informs Stockholders of the Actinium Pharmaceuticals, Inc. Class Action Lawsuit - PR Newswire
Rosen Law Firm Urges Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - Business Wire
ROSEN, A LEADING LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure - Bluefield Daily Telegraph
ROSEN, A LEADING LAW FIRM, Encourages Actinium - GlobeNewswire
ROSEN, A LEADING LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATNM - TradingView
ATNM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Actinium Pharmaceuticals, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Actinium Pharmaceuticals, Inc. (ATNM) - TradingView
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Actinium Pharmaceuticals, Inc. (ATNM) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm - TradingView
Actinium Pharmaceuticals unveils non-PSMA-targeting Ac-225 radiotherapy for prostate cancer - BioWorld MedTech
Actinium Pharmaceuticals ($ATNM) Misleading Trial Results and FDA Approval Case - TradingView
Actinium Pharmaceuticals secures Ac-225 supply from Eckert & Ziegler - DOTmed
ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) - Business Wire
Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225 - PR Newswire
Actinium Pharmaceuticals unveils novel prostate cancer therapy By Investing.com - Investing.com Australia
Actinium Pharmaceuticals unveils novel prostate cancer therapy - Investing.com
Actinium Pharmaceuticals Provides Business Update After Presentation at Trump Mar-A-Lago Club Announcing Novel Non-PSMA Prostate Cancer Radiotherapy ATNM-400 and Outlining Revitalized Clinical Pipeline with 2025 Corporate Objectives - PR Newswire
Small biotech joins list of health companies taking a trip to Trump's Mar-a-Lago - Endpoints News
Actinium rises ahead of presentation at Trump Mar-a-Lago Club - MSN
Actinium stock rises ahead of Mar-a-Lago event (ATNM:NYSE) - Seeking Alpha
Actinium Pharmaceuticals to Present Business Update at Trump Mar-A-Lago Club Today - PR Newswire
Actinium Pharmaceuticals’ (ATNM) Buy Rating Reaffirmed at HC Wainwright - Defense World
Actinium (ATNM) Stock Gains Momentum Amid Key Investor Event - Stocks Telegraph
Actinium Expands into $B Market: Expert Reveals Breakthrough Cancer Programs - Stock Titan
Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities - Marketscreener.com
Major Breakthrough: Actinium Locks Critical Supply Deal for Revolutionary Cancer Treatment Development - Stock Titan
Did Actinium Pharmaceuticals, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky InvestigateATNM - ACCESS Newswire
Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities - PR Newswire
Major Cancer Breakthrough: Actinium and MSK Join Forces to Transform AML Treatment Landscape - Stock Titan
Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy - PR Newswire
Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Cl - Longview News-Journal
Actinium Pharmaceuticals launches clinical trial for Actimab-A in combination - Yahoo Finance
Actinium Pharmaceuticals Launches Clinical Program to Evaluate Actimab-A as Combination Cancer Therapy - Marketscreener.com
Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO - Longview News-Journal
Actinium's New Cancer Trial Combines Actimab-A With Blockbuster PD-1 Drugs500,000 Patient Opportunity - Stock Titan
Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia - Longview News-Journal
Game-Changing Leukemia Treatment Extends Survival 6x Longer Than Standard Therapy - Stock Titan
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives $7.40 Consensus Price Target from Analysts - Defense World
HC Wainwright Reiterates “Buy” Rating for Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Actinium Pharmaceuticals to Participate at the 37th Annual Roth Conference - Citizentribune
Leading Radiotherapy Company Actinium Opens Exclusive Investor Access at ROTH 2025 - StockTitan
Actinium begins new Actimab-A trial combining Venetoclax and ASTX-727 to treat patients newly diagnosed with AML in partnership with NCI - Marketscreener.com
Actinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly Diagnosed AML - PR Newswire
Actinium Pharmaceuticals stock hits 52-week low at $1.07 By Investing.com - Investing.com Canada
BriaCell Therapeutics (NASDAQ:BCTX) versus Actinium Pharmaceuticals (NYSE:ATNM) Critical Analysis - Defense World
Actinium Pharmaceuticals stock hits 52-week low at $1.1 - MSN
25,000 Shares in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Purchased by Vontobel Holding Ltd. - Defense World
Actinium Pharmaceuticals (NYSE:ATNM) Shares Up 4.5% – What’s Next? - Defense World
3.89%
0.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):